Led by better-than-expected growth across export geographies and efficient cost control measures, most of the I-Direct coverage companies have reported beat on all fronts. Revenues of I-Direct pharma universe grew 14.3% YoY to | 45470 crore. Overall US pie reported one of the best results in the recent past due to 1) volume gains 2) mitigating base business price erosion 3) new launches and 4) currency tailwinds. Indian formulations growth was impacted mainly due slow growth in acute segment and high base of restocking of inventories. Margins performance was better-than...